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Abstract  
 
Aims: Adherence with non-vitamin-K oral anticoagulants (NOACs) may be lower than 
vitamin-K antagonists because NOACs do not require routine monitoring. We assessed the 
impact of an educational program on adherence and persistence with apixaban in patients with 
non-valvular atrial fibrillation (NVAF). 
Methods and results: Patients with NVAF eligible for NOACs with ≥1 stroke risk factor (prior 
stroke/transient ischemic attack, age ≥75 years, hypertension, diabetes or symptomatic heart 
failure) were randomized (1:1) to standard-of-care (SOC) or SOC with additional educational 
(information booklet, reminder tools, virtual clinic access). Primary outcome: adherence to 
apixaban (2.5 or 5 mg twice daily) at 24 weeks. Patients receiving the educational program 
were re-randomized (1:1) to continue the program for 24 further weeks or switch to secondary 
SOC. Implementation adherence and persistence were reassessed at 48 weeks.  
Results: In total, 1162 patients were randomized (SOC, 583; educational program, 579). Mean 
implementation adherence ± SD at 24 weeks was 91.6% ± 17.1 for SOC and 91.9% ± 16.1 for 
the educational program arm, respectively; results did not differ significantly between groups 
at any time-point. At 48 weeks, implementation adherence was 90.4% ± 18.0, 90.1% ± 18.6, 
and 89.3% ± 18.1 for continued educational program, SOC, and secondary SOC, respectively; 
and corresponding persistence (95% CI) was 86.1% (81.3 to 89.7), 85.2% (81.5 to 88.2), and 
87.8% (83.4 to 91.1). Serious adverse events were similar across groups.  
Conclusion: High implementation adherence and persistence with apixaban were observed in 
NVAF patients receiving apixaban. The educational program did not show additional benefits.   
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Key points 
 Patients with non-valvular atrial fibrillation who do not receive adequate anticoagulation 
are at increased risk of embolic events versus those continuously receiving the 
recommended treatment; poor adherence to anticoagulation can impact stroke protection 
 This was the first prospective, randomized, study investigating the impact of an education 
program on total days of adherence and persistence to a non-vitamin K oral anticoagulant 
(apixaban) 
 Implementation adherence and persistence rates were high over the first 48 weeks of 
administration, with attrition over time, with or without additional patient education; lack 
of impact of the educational intervention may be related to the experience of the 
investigators (high level of standard care) and limited uptake of digital support strategies.   
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1 Introduction 
Vitamin-K antagonists (VKAs) are highly effective for stroke prevention in non-valvular atrial 
fibrillation (NVAF), reducing the risk by about two thirds [1]. However, VKAs have 
drawbacks limiting their use: extensive drug and food interactions, narrow therapeutic range, 
and need for frequent international normalized ratio (INR) monitoring and dose adjustments 
[1]. Accordingly, ongoing patient education is necessary with VKA treatment. 
In patients with NVAF, non-VKA antagonist oral anticoagulants (NOACs) are at least 
as effective as warfarin for preventing stroke or systemic embolism (SE), while reducing the 
risk of intracranial hemorrhage by half [2–6]. In particular, apixaban has shown superiority 
over warfarin in preventing stroke or SE and is associated with lower risk of major bleeding 
complications and mortality [2]. NOACs have fewer food and drug interactions than VKAs, 
and do not require routine coagulation monitoring, overcoming many of the limitations of 
VKAs [7].  
In the absence of routine anticoagulation monitoring, it is important that patients treated 
with NOACs take their medication as prescribed during all three phases of adherence: initiation 
(when the first dose is taken); implementation (the extent to which a patient’s actual dosing 
corresponds to the prescribed dosing); and persistence (absence of discontinuation defined as 
the time when the next dose is omitted and no more doses are taken) [8]. Poor adherence may 
decrease protection from stroke [9].  
There is limited information on adherence to NOACs during the implementation phase, 
and most studies have instead described persistence. Compared with warfarin, persistence (at 
2.0, 1.9, 2.8, and 1.8 years) with NOACs in pivotal trials has been shown to be lower for 
dabigatran, similar for rivaroxaban or edoxaban, and higher with apixaban, respectively [2–6]. 
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Dedicated educational interventions aim to improve adherence by improving patients’ 
understanding of NVAF, goals of treatment, and risks associated with non-adherence. Many 
observational studies, but only a few small randomized clinical studies, have specifically 
investigated the impact of educational programs on adherence to warfarin [10,11]. While there 
have been several observational studies assessing adherence to NOACs [12–19], no studies 
have investigated the impact of education on NOAC adherence in NVAF patients. 
This study, the Assessment of an Education and Guidance program for Eliquis 
Adherence in non-valvular Atrial fibrillatioN (AEGEAN), investigated the impact of a 
proactive educational program on implementation adherence (from first administration of 
apixaban to discontinuation/completion of follow up) and persistence, using an electronic 
monitoring device (EMD) that recorded detailed information on the timing of medication 
access [20].  
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2 Methods 
2.1 Study population 
This Phase 4 randomized study was conducted at 171 sites in seven European countries 
(Belgium, France, Germany, Italy, Spain, Switzerland, and the United Kingdom). Patients with 
newly diagnosed or existing documented NVAF or atrial flutter, and a CHADS2 score ≥1 were 
eligible. Patients were either VKA-experienced (≥3 months’ treatment; target was one-third of 
randomized population) or VKA-naïve (≤30 days’ VKA treatment in the last 12 months). All 
patients were NOAC-naïve.  Patients with NVAF or atrial flutter who were receiving aspirin at a 
dose of ≤165 mg once daily for an indication other than atrial fibrillation were eligible. 
Patients were excluded if they: had other conditions requiring anticoagulation; had 
conditions associated with increased risk of hemorrhage; were at high risk of bleeding (e.g. due 
to other concomitant antiplatelet treatment or as a result of elective surgery or invasive 
procedures); were unable to self-administer study medication; were hospitalized; or were in 
long-term residential care (full details in the Online Appendix). 
Patients consented to, and initiated therapy with, apixaban (Eliquis®, Bristol-Myers 
Squibb/Pfizer EEIG, Uxbridge, United Kingdom) and were subsequently asked to participate 
in the monitoring phase of the study. Following consent to participate, patients were centrally 
randomized (via electronic case report form) in a 1:1 ratio to receive ‘standard of care’ (SOC) 
patient information or an additional educational program. After 24 weeks, patients receiving 
the educational program were re-randomized 1:1 to continue receiving the educational program 
or switch to SOC for an additional 24 weeks (Fig. 1). The trial design and the protocol were 
approved by relevant national regulatory authorities and by national and/or local ethics 
committees. All patients provided written informed consent. The trial is registered at: 
www.clinicaltrials.gov: NCT01884350. 
9 
 
2.2 Study procedures 
Most patients received standard apixaban 5 mg tablets twice daily for 48 weeks. Apixaban 
2.5 mg tablets twice daily were allocated to patients with creatinine clearance of 15–29 
ml/min or ≥2 of the following: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥133 
µmol/l. Commercial packages (over-labelled for clinical trial use only, according to country 
regulations) were provided. All sites were provided with 5 mg tablets and 2.5 mg tablets in 
separately labelled, numbered packs. During the telephone randomisation procedure, the dose 
reduction criteria were entered, and the site staff were advised which subject pack they would 
dispense (5 mg packs or 2.5 mg packs), according to the dose reduction criteria for apixaban in the 
approved SmPC. Sites were allocated a new patient pack with the appropriate dose for any 
subsequent dose reduction required (at a subsequent visit).  
Patients were asked not to break 5 mg tablets of apixaban if they were allocated to the 2.5 mg dose 
twice daily, nor take two 2.5 mg tablets of apixaban if they were allocated to 5 mg twice daily dose. 
The electronic monitoring device (EMD) could accommodate blister packs of either dosage. 
All patients received SOC information about apixaban treatment from the investigator and the 
standard patient information leaflet and information card, according to the usual practice at 
each study center. Patients assigned to the additional educational program also received: i) a 
patient education booklet explaining NVAF and anticoagulant treatment for stroke prevention; 
ii) one or more of the reminder tools (chosen at patient’s discretion): key ring, short message 
service alert on mobile phone, or smartphone application; and iii) access to a virtual clinic 
organized at country level utilizing staff from an existing anticoagulant clinic (virtual clinic 
locations listed in Online Resource 3). Patients were called by the virtual clinic within one 
week of randomization to ensure they had correctly understood the disease, rationale for 
anticoagulant treatment and importance of adherence. They were also given general 
information and advice regarding anticoagulant treatment, information on symptoms for 
bleeding or thromboembolic events, and a toll-free number for further questions. Follow-up 
calls to reinforce the importance of adherence and provide additional advice (if needed) 
occurred 10–20 days after the first call and monthly thereafter. Patients could call the virtual 
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clinic as often as needed. All information was provided using the official local language(s). 
After randomization, there were 5 visits scheduled during the study (weeks 4, 12, 24, 36, and 
48; Online Table 1). 
2.3 Outcome measures 
The primary outcome was implementation adherence of the dosing regimen (the proportion of 
days adhering to the prescribed regimen) at 24 weeks, assessed using an EMD, Helping Hand® 
(WestRock Switzerland Ltd., Sion, Switzerland), an established monitoring device previously 
utilized in adherence studies [21–24]. The basic model (model number: 1110-01) was 
employed in this study, which had no display or reminder function to enhance implementation 
(see Online Fig. 1). The EMD was operated by inserting commercial blister packs into the 
device, which then electronically recorded every time the blister was removed (date and time). 
It was assumed that a single dose of study medication was administered every time the blister 
pack was removed. Sites uploaded data from the device at every study visit, but investigators 
and patients remained blinded to the data. The secondary outcome of the study was 
implementation adherence to the dosing regimen at 48 weeks. Days of adherent and non-
adherent implementation were defined as: 
• Day of adherent implementation: 24-hour window during which  
- the treatment was taken twice daily as prescribed (one tablet two times a day)  
- only one isolated tablet was missed in 24 hours and no tablet was missed the previous 
day or the day after) (see exception below). 
• Day of non-adherent implementation: 24-hour window during which  
- two consecutive tablets within 24 hours were missed  
- one tablet was missed for several consecutive days, with the first day considered a 
day of adherent implementation 
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- one tablet was missed on alternate days, every second day with a missed tablet 
constituting a day of non-adherent implementation. 
The details on how adherence units were calculated can be found in the submitted statistical 
analysis plan (Electronic Supplementary Material, Section 8.4.2). Thus, the primary outcome is a 
measure of the optimality of medication intake and reflects both implementation and 
persistence, with any non-persistent period corresponding to non-adherent days. Other study 
objectives included: percentage of “persistent” patients (i.e. those patients who  temporarily, but 
not permanently, discontinued their treatment regimen at the discretion of the investigator), and 
evaluation of the effect of the educational program on clinical outcomes (death, myocardial 
infarction, stroke, transient ischemic attack or SE, venous thromboembolism, major bleeding 
[non-fatal] or clinically relevant non-major bleeding, and fatal bleeding). Bleeding events were 
defined according to the International Society on Thrombosis and Haemostasis criteria (Online 
Resource 4). All ischemic, hemorrhagic events and deaths were adjudicated by an independent 
committee (Online Resource 2) who were blinded to patients’ study group. 
2.4 Statistical analysis 
The study had 85% power to detect a between-group difference of 4% in the percentage of days 
with a correct execution of the dosing regimen during 24 weeks, assuming an intra-group 
standard deviation (SD) of 21.1%. Anticipating a dropout rate of 10%, 1112 patients, 556 per 
group, were needed to obtain a sample size of approximately 1000 evaluable patients (primary 
outcome analysis).  
The primary outcome, calculated as the percentage of days of implementation 
adherence during the period for each study group, was tested by the two-sample independent 
t-tests at the 5% significance level (two-sided). Only the time period for which patients were 
persistent was taken into consideration for the analysis. Homogeneity of variances was checked 
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graphically and with the F-test. The Cochran t-test was used for unequal variances between the 
two groups. 
Within each study group, the percentage of days with a correct execution of apixaban 
dosing during the first 12, 12–24, and 24–48-week periods was compared using a paired t-test, 
at a 2-sided α level of significance of 0.05. 
The percentage of patients within each group who were “persistent” over time was 
described using Kaplan-Meier estimates. If treatment with apixaban was withheld temporarily by 
the investigator during the study period, the time window during which apixaban was withheld was 
not considered for adherence measurement purposes. Study treatment that was withheld for more 
than 30 consecutive days was considered a permanent discontinuation. 
Descriptive statistics were used to summarize clinical outcomes per group to evaluate 
the effect of the educational program on efficacy and safety outcomes. The study was not 
powered to detect outcome differences between the groups.  
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3 Results 
3.1 Patients and procedures 
Between November 21, 2013, and December 19, 2014, 1228 patients consented and were 
enrolled in the AEGEAN study. Among them, 1162 were randomized to either SOC (n = 583) 
or the additional educational program (n = 579). Of 524 patients remaining in the additional 
educational program at week 24, 263 were re-randomized to SOC (secondary SOC) and 261 
continued the additional educational program to week 48 (patient flow shown in Online Fig. 
2). Baseline patient characteristics were well balanced between the two initial randomized 
groups (Table 1).  
The proportions of patients communicating with the virtual clinic and using reminders at  
24 weeks are presented in Online Table 2. Overall, >95% of patients in the additional education 
program group had communicated with the virtual clinic during the first 24 weeks. The 
majority of patients used the home phone (>80%) as the preferred method of communication 
with the clinic and dose reminders (>40%) as the preferred type of reminder. Few (<1%) 
patients used email or a smartphone app. Nearly half (45.3%) of patients in the additional 
education program group chose to receive one reminder; few patients (<1%) chose to receive 
two reminders. 
3.2 Implementation adherence and persistence  
In the additional educational program group, the mean ± SD (median [min, max]) percentage 
of days of implementation adherence (i.e. the primary outcome) was 91.9% ± 16.1% (98.2% 
[3%, 100%]) (Fig. 2). In the SOC group, the mean implementation adherence was 91.6% ± 
17.1% (98.2% [1%, 100%]) (Fig. 2). By 48 weeks, implementation adherence had declined to 
90.4% ± 18.0% (97.3% [2%, 100%]) in the continued additional educational program group; 
90.1% ± 18.6% (97.9% [1%, 100%]) in the SOC group; and 89.3% ± 18.1% (97.9% [2%, 
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100%]) in the secondary SOC group. There were no significant differences between groups at 
24 or 48 weeks (Fig. 3; P>0.7 for all between-group comparisons). Up to 48 weeks, the average 
percentage of missed doses was low in each of the additional educational program, SOC and 
secondary SOC groups (24 weeks: 4.4% ± 8.2%, 4.9% ± 8.5%, and 4.7% ± 7.2%, respectively; 
48 weeks: 4.9% ± 8.6%, 5.9% ± 9.3% and 5.7% ± 7.8%). 
Persistence declined gradually across 48 weeks in all groups (Fig. 4). However, the percentage 
of patients (95% confidence interval [CI]) persistent at 48 weeks was high: 86.1% (81.3 to 
89.7%), 85.2% (81.5 to 88.2%), and 87.8% (83.4 to 91.1%) in the continued additional 
educational program, SOC, and secondary SOC groups, respectively (P>0.5 for all between-
group comparisons). At week 48, only 9.2% (n = 100) of patients had missed three consecutive 
doses at any time during the study period. At this timepoint, the mean ± SE percentage of days 
of implementation adherence was 90.8% ± 18.0% (median 98.1% [1%, 100%]) in previously 
VKA-treated patients and 89.6% ± 18.5% (97.6% [2%, 100%]) in VKA-naïve patients 
(P=0.32). In addition, the likelihood of having <80% implementation adherence in previously 
VKA-treated and VKA-naïve patients was similar in all groups (P>0.05 for all between-group 
treatment comparisons). 
Comparisons of implementation adherence between the SOC and the additional 
educational program for different subgroups of patients demonstrated no significant differences 
in the likelihood of having <80% implementation adherence (Online Fig. 3; P>0.1 for all 
subgroup comparisons). 
3.3 Clinical outcomes 
Adjudicated clinical events are summarized in Table 2. Overall, 4.8% of patients had at least 
one adverse event leading to permanent discontinuation (4.5% in the additional educational 
group and 5.1% in the SOC group). Between 24 and 48 weeks, 2.2% of patients had an adverse 
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event leading to permanent discontinuation (1.1%, 2.2%, and 3.0% in the additional 
educational, SOC, and secondary SOC groups, respectively). Bleeding events were low and 
evenly distributed across groups (Table 2).  
 
4 Discussion 
This was the first prospective, randomized, study investigating the impact of an education 
program on adherence to a NOAC. In daily practice, many patients do not adhere to life-saving 
treatments or to treatments that can prevent serious complications and/or improve quality of 
life [8,25–27]. However, strict implementation of NOAC intake is crucial because its 
anticoagulant effect wanes within 12–24 h after the last intake [7]. The AEGEAN study showed 
that implementation adherence and persistence rates with apixaban therapy for NVAF are high 
over the first 48 weeks of administration (~90% for the implementation phase), with attrition 
of implementation adherence and persistence over time. While most studies present rates of 
adherent patients, rather than the total days of adherence as per the primary outcome in this 
study, rates of persistence compare favorably with previously reported rates in other NOAC 
studies (persistence of 56–74% over a median follow-up duration of up to 36 weeks) 
[17,28,29]. However, these studies were retrospective with significant measurement bias 
[28,29]. Although the deployment of a 24- or 48-week proactive educational program in the 
AEGEAN study did not substantially increase the implementation adherence and persistence 
rates, the very high SOC rates are encouraging, and these data are consistent with the reported 
data for apixaban [28,29]. The adherence and persistence findings may reflect the impact of 
continued follow-up of patients in the SOC group, with five follow-up visits in the first year, 
the importance of providing appropriate NOAC-specific information at initiation (as 
recommended [30]), as well as the use of the EMD. While the EMD used in this study did not 
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incorporate a reminder function, the monitoring of medication use in itself could act as a 
continuous reminder (the Hawthorne effect) [31] and also act as a motivator for implementation 
adherence. In the AEGEAN study, adherence data feedback was not possible in order to 
maintain the double-blind aspect of the study. However, a recently published telemonitoring 
study, using daily patient feedback and employing an EMD, has shown very high adherence 
(89.6% over a 3-month observation period) to NOAC therapy despite the small sample size, 
probably largely attributable to being monitored [18].  
Implementation adherence and persistence rates reported with VKAs are generally 
lower than those with NOACs, with historical cohort studies and clinical trials reporting rates 
of 42–78% (duration of follow-up of 3–84 months) [9]. This may be attributed to burdensome 
therapeutic monitoring and dose-adjustment requirements associated with these agents [32], as 
well as drug-drug and drug-food interactions that need to be explained in detail at treatment 
initiation, and which require ongoing education. One-third of the patients in AEGEAN were 
VKA-experienced and switched to apixaban at randomization. In these patients, 
implementation adherence in the SOC group was similar to that observed in anticoagulant-
naïve patients.  
The lack of a significant benefit of our proactive educational program on apixaban 
implementation adherence and persistence was unexpected. In addition to the high 
implementation adherence rate with SOC (~90%), several factors may have offset the effect of 
the educational program; i) investigators in the AEGEAN trial are likely to be more 
experienced and well trained in prescribing NOACs and providing more NOAC-specific 
information than the general population of physicians, narrowing the gap between SOC patient 
information and the additional educational program; ii) limited patient uptake of dose reminder 
strategies, especially those associated with email and cell phones, possibly because of the 
advanced age of the patients; and iii) the nature of the virtual clinic, as recent findings suggest 
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that face-to-face engagement can maximize effectiveness [17]. Nonetheless, the virtual clinic 
contacted patients in the intervention arm regularly and proactively, albeit remotely, which 
would act as an intermittent reminder for medication adherence, and most virtual clinics 
reported positive patient interactions. It is also possible that a major differential effect would 
be expected on the initiation phase of adherence (patients who start/do not start treatment), 
which was not measured in this study as most patients had initiated treatment in hospital. 
Finally, lack of observed effect from similar educational programs has been reported in clinical 
situations other than NVAF [33,34], reinforcing the difficulty of such initiatives. In contrast, 
the recent FACILITA study showed that a mixed intervention, consisting of patient education 
and a simple calendar reminder of drug intake, was an effective strategy to improve dabigatran 
adherence (to 91% and 89% at 6 and 12 months, respectively, compared with 65% and 63% 
for the control group) [19]. Also, in the IMPACT-AF study, the use of oral anticoagulation in 
patients with atrial fibrillation was improved by a multifaceted and multilevel educational 
program, where the provision of physician education targeted the initiation phase of adherence 
as well as the implementation and persistence phases [35]. However, there were notable 
differences compared with the present study. The majority of patients in IMPACT-AF (>80%) 
were anticoagulated with VKA, with poor implementation of treatment at baseline (66%) 
leaving room for a significant improvement after intervention. Moreover, education was 
provided not only to patients but also to their families and healthcare providers, an important 
aspect of VKA treatment. There was also regular monitoring with a feedback mechanism 
providing relevant information to coordinating centers, such as notifications when patients 
were not taking their drugs and allowing physician intervention to prevent discontinuation of 
anticoagulation and improve persistence [35]. Despite these efforts, the persistence rate 
observed in IMPACT-AF remained lower than that seen in the current study.  
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 Our study has limitations. Selection of participating patients may not fully represent 
patients in real life, as patients willing to participate in an adherence study are more likely to 
be better adherers. Furthermore, patient consent to participate in the implementation phase was 
only obtained once patients had consented to initiate apixaban therapy. Thus, patients who did 
not consent to the study, possibly due to lack of motivation (and who might have exhibited 
poorer implementation adherence or persistence) were not included in the trial. While the 
follow-up schedule was selected to be close to the SOC for most countries, in some centers this 
would constitute additional visits that may have acted as a reminder and improved 
implementation adherence. Present results apply to the duration of the study and adherence 
may further decrease over time beyond 48 weeks - we do not know the impact of education 
beyond this period. Measuring implementation adherence improves it per se, as the patient is 
aware they are being monitored, resulting in overestimation. However, this effect was 
minimized because neither the patient nor the investigator was aware of the implementation 
adherence data during the trial. AEGEAN used a low-bias, rich sampling method (EMD 
Helping Hand®) that precisely recorded the date and time of medication access, providing 
detailed information on implementation adherence (although pill disposal after extraction from 
the packet cannot be ruled out) [20]. The type of EMD used may also have influenced results 
across the study, as some models with displays provide instant feedback. Instant positive 
feedback following intake of medication may encourage future implementation adherence and 
persistence; thus, it is possible that overall adherence across all cohorts would increase if EMDs 
with displays were used. We believe our definition of a unit of non-adherence in 
implementation (missing two consecutive pills) is conservative. It has been argued that missing 
three consecutive doses of an oral anticoagulant with a 12-hour half-life would have the same 
impact on its pharmacokinetic profile as missing one (double) dose in a once-daily regimen 
[36]. Thus, it is likely that the lower limit of apixaban’s therapeutic window, where the risk of 
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thrombosis begins to increase, is reached only after missing three or more doses. While the cost 
of medication may also impact implementation adherence and persistence, medications were 
fully reimbursed in all countries that participated in this study and therefore medication 
acquisition costs would not have impacted the outcome. Finally, the study enrolled patients 
with AF who were relatively stable compared with an unselected AF population, as 
hospitalized patients and those with an increased risk of bleeding were excluded. This may 
have reduced the occurrence of clinical events such as bleeding, which could have impacted 
adherence and reduced the effect of the educational program on this outcome. 
In conclusion, our study demonstrated high implementation adherence and persistence 
rates during the first 48 weeks in patients started on apixaban for NVAF, and highlighted the 
importance of regular patient follow-up and education in maintaining favorable adherence to 
NOAC therapy in both SOC and intervention arms of the study.  
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Figure legends 
Fig. 1 Study design 
Patients consented to and initiated therapy with apixaban and were subsequently asked to 
participate in the implementation phase of the study. Following consent, patients were centrally 
randomized in a 1:1 ratio to receive SOC patient information or an additional educational 
program. 
ASA, acetylsalicylic acid; OAC, oral anticoagulant; NVAF, non-valvular atrial fibrillation; R, randomization; 
SOC, standard of care; VKA, vitamin-K antagonist. 
For subject discontinuations see Online Table 3. 
 
Fig. 2 Implementation of the correct apixaban dose by study group at week 24 (mean; primary 
outcome)  
Implementation adherence (treatment taken as prescribed with ≤1 dose missed within 24 hours 
and no tablet missed on the previous two consecutive days) was monitored by an electronic 
monitoring device. Not all patients handed in the device at week 24.  
 
Fig. 3 Overall implementation of the correct apixaban dose (mean) by study group 
Apixaban with standard-of-care, patients randomized to receive only standard-of-care 
information following apixaban initiation; Apixaban with additional educational program, 
patients randomized to receive an additional educational program following apixaban 
initiation; Apixaban with secondary standard-of-care, patients with educational program 
switched to standard-of-care information only following 24 weeks’ apixaban treatment. 
Additional data from all patients handing in the device at the end of the trial were included for 
calculating implementation adherence by week, up to week 48.  
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Fig. 4 Persistence by study group over 48 weeks (secondary outcome) 
Apixaban with standard-of-care, patients randomized to receive only standard-of-care 
information following apixaban initiation; Apixaban with additional educational program, 
patients randomized to receive an additional educational program following apixaban 
initiation; Apixaban with secondary standard-of-care, patients with educational program 
switched to standard-of-care information only following 24 weeks’ apixaban treatment. 
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Table 1 Baseline patient characteristics 
 Additional 
Educational Program 
(Na = 579) 
(n, % or ±SD) 
Primary SOC 
(Na = 583) 
(n, % or ±SD) 
 
Age, years 73.1 ± 9.1           72.6 ± 8.9           
 Age ≥75 years 282 (48.7)          276 (47.3)          
Female 234 (40.4)          232 (39.8)          
Weight, kg 81.7 ± 16.7          82.8 ± 17.7          
Heart rate, bpm 74.9 ± 16.7          74.3 ± 15. 9          
Systolic blood pressure, mmHg 132.7 ± 16.4         135.0 ± 17.1         
Diastolic blood pressure, mmHg 78.0 ± 10.7          79.5 ± 10.8          
MMSE 28.2 ± 1.7           28.3 ± 1.6           
Type of diagnosis   
Atrial fibrillation 557 (96.4)         562 (96.4)          
Atrial flutter 19 (3.3)           18 (3.1)           
Atrial fibrillation + atrial flutter                                     2 (0.3)    3 (0.5)            
Type of non-valvular atrial fibrillation   
Paroxysmal 301 (52.4)          280 (48.4)          
Persistent 137 (23.9)          148 (25.6)          
Permanent 136 (23.7)          150 (26.0)          
Stroke and bleeding risk factors   
Congestive heart failure 93 (16.1)          83 (14.2)           
Hypertension 497 (85.8)         516 (88.5)         
Diabetes mellitus 151 (26.1)          154 (26.4)          
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 Additional 
Educational Program 
(Na = 579) 
(n, % or ±SD) 
Primary SOC 
(Na = 583) 
(n, % or ±SD) 
 
History of stroke or TIA 107 (18.5)          94 (16.1)          
History of coronary heart disease/stent 
or PVD 
142 (24.5)          138 (23.7)          
Renal failureb 11 (1.9)           7 (1.2)           
CHADS2 2.1 ± 1.0            2.1 ± 1.1            
CHA2DS2-VASc 3.6 ± 1.3            3.6 ± 1.4            
HAS-BLED 1.7 ± 0.8            1.7 ± 0.8            
 High risk of bleeding (HAS-BLED ≥3) 87 (15.2)          87 (15.1)           
Baseline VKA status   
VKA-naïvec 370 (63.9)          371 (63.6)          
VKA-treatedd 207 (35.8)          210 (36.0)          
Number of concomitant medications at 
baseline 
5.1 ± 2.9            5.0 ± 2.7            
Previous treatment with ASA 114 (19.7)            116 (19.9)          
Concomitant treatment with ASA 100 (17.9) 89 (14.8) 
Dose of study drug assigned at baseline   
5 mg 499 (86.2)         512 (88.1)          
2.5 mg 80 (13.8)          69 (11.9)           
 
Values are mean ± SD or n (%).  
aN represents the number of patients contributing to summary statistics. All percentages are based on the 
number of patients with available data for each characteristic. 
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bCreatinine clearance below 30 ml/min. 
cVKA-naïve patients must not have received VKA treatment for more than 30 days within the last 12 months. 
dVKA-treated patients must have received the VKA treatment for >3 months. 
ASA, acetylsalicylic acid; MMSE, Mini Mental State Examination; PVD, peripheral vascular disease; SD, 
standard deviation; SOC, standard-of-care; TIA, transient ischemic attack; VKA, vitamin-K antagonist. 
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Table 2 Adjudicated clinical endpoints at 24 and 48 weeks’ follow-up 1 
 24 WEEKS 24-48 WEEKS 
 Apixaban, AEP 
(N = 583) 
Apixaban, pSOC  
(N = 579) 
Apixaban, AEP 
(N = 261) 
Apixaban, pSOC  
(N = 583) 
Apixaban, sSOC  
(N = 263) 
 Patients 
N (%) 
Events 
N 
Patients 
N (%) 
Events 
N 
Patients 
N (%) 
Events 
N 
Patients 
N (%) 
Events 
N 
Patients 
N (%) 
Events 
N 
 
Death 4 (0.7) 4 4 (0.7) 4 1 (0.4) 1 1 (0.2) 1 3 (1.1) 3 
Cardiovascular death 2 (0.3) 2 4 (0.7) 4 0  0 1 (0.2) 1 2 (0.8) 2 
Stroke, TIA, SE 5 (0.9) 6 1 (0.2) 1 1 (0.4) 1 1 (0.2) 1 3 (1.1) 3 
Ischemic stroke 0  0 1 (0.2) 1 1 (0.4) 1 0  0 0  0 
Hemorrhagic stroke 2 (0.3) 3 0 0 0  0 0  0 1 (0.4) 1 
TIA 0 0 0 0 0  0 1 (0.2) 1 1 (0.4) 1 
SE 3 (0.5) 3 0 0 0  0 0  0 1 (0.4) 1 
Myocardial infarction 4 (0.7) 4 2 (0.3) 2 0  0 1 (0.2) 1 0  0 
Venous thromboembolism 1 (0.2)a 1 0 0 1 (0.4) 1 0  0 0 0 
Pulmonary embolism 1 (0.2) 1 0 0 0  0 0  0 0  0 
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Deep-vein thrombosis 1 (0.2) 1 0 0 1 (0.4) 1 0  0 0  0 
MB (non-fatal) or CRNMB 9 (1.6)b 10 7 (1.2) 7 0  0 2 (0.3) 2 2 (0.8) 2 
MB (non-fatal) 4 (0.7) 4 2 (0.3) 2 0 0 2 (0.3) 2 1 (0.4) 1 
CRNMB 5 (0.9) 5 5 (0.9) 5 0  0 0  0 0  0 
Fatal bleeding 1 (0.2) 1 0 0 0 0 0  0 1 (0.4) 1 
aOne patient, who had one event of deep-vein thrombosis + pulmonary embolism.  2 
bOne patient had a major and a fatal bleeding. 3 
AEP, additional educational program; CRNMB, clinically relevant non-major bleeding; MB, major bleeding; pSOC, primary standard-of-care; SE, systemic embolism; sSOC, 4 
secondary standard-of-care; TIA, transient ischemic attack. 5 
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Fig. 1 Study design 
  
 
 
 
 
 
 
 
 
 
 
 
Patients consented to and initiated therapy with apixaban and were subsequently asked to 
participate in the implementation phase of the study. Following consent, patients were centrally 
randomized in a 1:1 ratio to receive SOC patient information or an additional educational 
program. 
ASA, acetylsalicylic acid; OAC, oral anticoagulant; NVAF, non-valvular atrial fibrillation; R, randomization; 
SOC, standard of care; VKA, vitamin-K antagonist. 
For subject discontinuations see Online Table 3. 
  
 OAC indication 
 NVAF patients 
 VKA-treated 
(1/3) 
 VKA-naïve (2/3) 
 ASA-treated 
allowed 
24 weeks 24 weeks 
Apixaban with primary 
standard-of-care education  
Randomized (n = 583) 
Received (n = 581) 
Completed 24 wks (n = 529) 
Apixaban with additional 
educational programme  
Randomized (n = 579) 
Received (n = 579) 
Completed 24 wks (n = 525) 
Apixaban with primary 
standard-of-care 
Randomized (n = 0) 
Received (n = 512) 
Completed 48 wks (n = 503) 
 
Apixaban with secondary 
standard-of-care 
Randomized (n=263) 
Received (n=253) 
Completed 48 wks (n=250) 
 
Apixaban with continued 
additional education 
programme 
Randomized (n = 261) 
Received (n = 254) 
Completed 48 wks (n = 250) 
Implementation 
adherence 
primary outcome 
Implementation 
adherence 
secondary outcome 
R 
R 
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Fig. 2 Implementation of the correct apixaban dosing by study group at week 24 (mean; 
primary outcome)  
 
Implementation adherence (treatment taken as prescribed with ≤1 dose missed within 24 hours 
and no tablet missed on the previous two consecutive days) was monitored by an electronic 
monitoring device. Not all patients handed in the device at week 24.  
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Fig. 3 Overall implementation of the correct apixaban dosing (mean) by study group 
 
P>0.7 for all between-group comparisons at 24 and 48 weeks. 
Apixaban with standard-of-care, patients randomized to receive only standard-of-care 
information following apixaban initiation; Apixaban with additional educational program, 
patients randomized to receive an additional educational program following apixaban 
initiation; Apixaban with secondary standard-of-care, patients with educational program 
switched to standard-of-care information only following 24 weeks apixaban treatment. 
Additional data from all patients handing in the device at the end of the trial, were included for 
calculating implementation adherence by week, up to week 48.  
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Fig. 4 Persistence by study group over 48 weeks (secondary outcome) 
 
Apixaban with standard-of-care, patients randomized to receive only standard-of-care 
information following apixaban initiation; Apixaban with additional educational program, 
patients randomized to receive an additional educational program following apixaban 
initiation; Apixaban with secondary standard-of-care, patients with educational program 
switched to standard-of-care information only following 24 weeks apixaban treatment. 
 
